BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726-1737. [PMID: 31042825 DOI: 10.1056/nejmoa1817226] [Cited by in Crossref: 507] [Cited by in F6Publishing: 235] [Article Influence: 253.5] [Reference Citation Analysis]
Number Citing Articles
1 Uckun FM. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers (Basel) 2021;13:2018. [PMID: 33922005 DOI: 10.3390/cancers13092018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Petty AJ, Heyman B, Yang Y. Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers (Basel) 2020;12:E842. [PMID: 32244520 DOI: 10.3390/cancers12040842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
3 Cui R, Li P, Li Q, Mu J, Jiang YL, Jiang YY, Deng Q. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:502-7. [PMID: 34384157 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.010] [Reference Citation Analysis]
4 Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med. 2020;45:279-297. [PMID: 31894255 DOI: 10.3892/ijmm.2019.4418] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
5 Motais B, Charvátová S, Hrdinka M, Šimíček M, Jelínek T, Ševčíková T, Kořístek Z, Hájek R, Bagó JR. A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers (Basel) 2020;12:E1333. [PMID: 32456165 DOI: 10.3390/cancers12051333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Legarda MA, Cejalvo MJ, de la Rubia J. Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers (Basel) 2020;12:E3576. [PMID: 33265952 DOI: 10.3390/cancers12123576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sidana S, Shah N. CAR T-cell therapy: is it prime time in myeloma? Hematology Am Soc Hematol Educ Program 2019;2019:260-5. [PMID: 31808895 DOI: 10.1182/hematology.2019000370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
8 Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, Young KH, Qian W. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:3912. [PMID: 34359816 DOI: 10.3390/cancers13153912] [Reference Citation Analysis]
9 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Qian Y, Qian Z, Zhao X, Pan W, Wei X, Meng H, Yang L, Xiao H. Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature. Front Med (Lausanne) 2021;8:649824. [PMID: 34026784 DOI: 10.3389/fmed.2021.649824] [Reference Citation Analysis]
11 Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in Multiple Myeloma. Cells 2020;9:E601. [PMID: 32138182 DOI: 10.3390/cells9030601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
12 Joshua DE, Vuckovic S, Favaloro J, Lau KHA, Yang S, Bryant CE, Gibson J, Ho PJ. Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. Front Immunol 2021;12:620596. [PMID: 33708212 DOI: 10.3389/fimmu.2021.620596] [Reference Citation Analysis]
13 Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868. [PMID: 33558511 DOI: 10.1038/s41467-021-21177-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
14 Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol 2021. [PMID: 34230645 DOI: 10.1038/s41571-021-00530-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Danhof S, Rasche L, Mottok A, Steinmüller T, Zhou X, Schreder M, Kilian T, Strifler S, Rosenwald A, Hudecek M, Einsele H, Gerhard-Hartmann E. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Ann Hematol 2021;100:1537-46. [PMID: 33575947 DOI: 10.1007/s00277-021-04447-6] [Reference Citation Analysis]
16 D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia 2020;34:21-34. [PMID: 31780814 DOI: 10.1038/s41375-019-0669-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 27.5] [Reference Citation Analysis]
17 Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers (Basel) 2020;12:E2523. [PMID: 32899464 DOI: 10.3390/cancers12092523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, Yumashev AV, Shomali N, Chartrand MS, Pathak Y, Mohammed RN, Jarahian M, Motavalli R, Motavalli Khiavi F. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Res Ther 2021;12:217. [PMID: 33781320 DOI: 10.1186/s13287-021-02283-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
20 Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 2021;5:2196-215. [PMID: 33890981 DOI: 10.1182/bloodadvances.2020003805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Suzuki K, Nishiwaki K, Yano S. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. Cancers (Basel) 2021;13:E215. [PMID: 33435539 DOI: 10.3390/cancers13020215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
22 Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, Hill JA. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight 2021;6:146743. [PMID: 33914708 DOI: 10.1172/jci.insight.146743] [Reference Citation Analysis]
23 Kanduri SR, Cheungpasitporn W, Thongprayoon C, Petnak T, Lin Y, Kovvuru K, Manohar S, Kashani K, Herrmann SM. Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. Kidney Int Rep 2021;6:1416-22. [PMID: 34013119 DOI: 10.1016/j.ekir.2021.02.013] [Reference Citation Analysis]
24 Einsele H, Briones J, Ciceri F, García-Cadenas I, Falkenburg F, Bolaños N, Heemskerk HMM, Houot R, Hudecek M, Locatelli F, Morgan K, Morris CE, O'Dwyer M, Gil JS, van den Brink M, van de Loosdrecht AA. Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. Hemasphere 2020;4:e423. [PMID: 32904089 DOI: 10.1097/HS9.0000000000000423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, Guo X, Lu X, Su F. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer 2021;20:5. [PMID: 33397398 DOI: 10.1186/s12943-020-01301-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 2020;11:6080. [PMID: 33247092 DOI: 10.1038/s41467-020-19486-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
27 Liu D. CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol 2019;12:113. [PMID: 31703740 DOI: 10.1186/s13045-019-0819-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
28 Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov 2021;20:531-50. [PMID: 33972771 DOI: 10.1038/s41573-021-00189-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
29 Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol 2020;11:608485. [PMID: 33658994 DOI: 10.3389/fimmu.2020.608485] [Reference Citation Analysis]
30 Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, Gao J. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. Front Immunol 2021;12:609421. [PMID: 33767695 DOI: 10.3389/fimmu.2021.609421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jasiński M, Basak GW, Jedrzejczak WW. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. Front Immunol 2021;12:632937. [PMID: 33717171 DOI: 10.3389/fimmu.2021.632937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest 2020;130:1586-94. [PMID: 32235098 DOI: 10.1172/JCI129208] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 25.0] [Reference Citation Analysis]
33 Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther Adv Hematol 2021;12:20406207211019622. [PMID: 34104374 DOI: 10.1177/20406207211019622] [Reference Citation Analysis]
34 Gurney M, O'Dwyer M. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. Cancers (Basel) 2021;13:1568. [PMID: 33805422 DOI: 10.3390/cancers13071568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Xie M, Viviani M, Fussenegger M. Engineering precision therapies: lessons and motivations from the clinic. Synth Biol (Oxf) 2021;6:ysaa024. [PMID: 33817342 DOI: 10.1093/synbio/ysaa024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Olnes MJ. Immune Therapies for Hematologic Malignancies. Cancers (Basel) 2021;13:295. [PMID: 33467389 DOI: 10.3390/cancers13020295] [Reference Citation Analysis]
37 Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol 2019;10:1613. [PMID: 31379824 DOI: 10.3389/fimmu.2019.01613] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
38 Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics 2020;12:E194. [PMID: 32102267 DOI: 10.3390/pharmaceutics12020194] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
39 Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J 2020;10:84. [PMID: 32829378 DOI: 10.1038/s41408-020-00350-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
40 Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 2021;11:23. [PMID: 33563906 DOI: 10.1038/s41408-021-00414-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S, Sharma P, Delfino F, Lin J, Smith E, Thurston G, Kirshner JR. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv 2021;5:1291-304. [PMID: 33651100 DOI: 10.1182/bloodadvances.2020002736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Poels R, Drent E, Lameris R, Katsarou A, Themeli M, van der Vliet HJ, de Gruijl TD, van de Donk NWCJ, Mutis T. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. Int J Mol Sci 2021;22:1096. [PMID: 33499253 DOI: 10.3390/ijms22031096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, Jaimes EA, Perales MA, Sathick J. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant 2020;26:1071-6. [PMID: 32088364 DOI: 10.1016/j.bbmt.2020.02.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
44 Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, Rattel B, Lamas E, Min X, Sudom A, Farshbaf M, Coxon A, Balazs M, Arvedson T. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv 2020;4:4180-94. [PMID: 32886754 DOI: 10.1182/bloodadvances.2020002565] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
45 Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol 2021;12:2040620721989585. [PMID: 33796236 DOI: 10.1177/2040620721989585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res 2021;128:1780-801. [PMID: 33934609 DOI: 10.1161/CIRCRESAHA.120.315894] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res 2020;26:6028-38. [PMID: 32917735 DOI: 10.1158/1078-0432.CCR-20-0400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J 2021;11:45. [PMID: 33649314 DOI: 10.1038/s41408-021-00440-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol 2021;39:757-67. [PMID: 33296242 DOI: 10.1200/JCO.20.02259] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
50 Jackson SW, Davidson A. BAFF inhibition in SLE-Is tolerance restored? Immunol Rev 2019;292:102-19. [PMID: 31562657 DOI: 10.1111/imr.12810] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
51 Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8:e001511. [PMID: 33335028 DOI: 10.1136/jitc-2020-001511] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 29.0] [Reference Citation Analysis]
52 Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 2019;3:3248-60. [PMID: 31698455 DOI: 10.1182/bloodadvances.2019000703] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 30.0] [Reference Citation Analysis]
53 Yang Y, Sun M, Yu Z, Liu J, Yan W, Liu Z, Wei M, Wang H. Designing high affinity target-binding peptides to HLA-E: a key membrane antigen of multiple myeloma. Aging (Albany NY) 2020;12:20457-70. [PMID: 33115963 DOI: 10.18632/aging.103858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther 2019;19:1143-56. [PMID: 31277554 DOI: 10.1080/14712598.2019.1641196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
55 Bruins WSC, Zweegman S, Mutis T, van de Donk NWCJ. Targeted Therapy With Immunoconjugates for Multiple Myeloma. Front Immunol 2020;11:1155. [PMID: 32636838 DOI: 10.3389/fimmu.2020.01155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 14.0] [Reference Citation Analysis]
56 Zahid A, Siegler EL, Kenderian SS. CART Cell Toxicities: New Insight into Mechanisms and Management. Clin Hematol Int 2020;2:149-55. [PMID: 33409484 DOI: 10.2991/chi.k.201108.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Schubert ML, Rohrbach R, Schmitt M, Stein-Thoeringer CK. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Front Immunol 2021;12:670286. [PMID: 34135898 DOI: 10.3389/fimmu.2021.670286] [Reference Citation Analysis]
58 Hosen N. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers (Basel). 2019;11:2024. [PMID: 31847470 DOI: 10.3390/cancers11122024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rübenthaler J, Brendel M, Subklewe M, von Bergwelt-Baildon M, Ricke J, Kunz WG, Cyran CC. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 2020;4:63. [PMID: 33200246 DOI: 10.1186/s41747-020-00190-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
60 Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther 2020;9:201-15. [PMID: 33117743 DOI: 10.2147/ITT.S240886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
61 Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 2020;13:164. [PMID: 33272302 DOI: 10.1186/s13045-020-01001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
62 Rodríguez-Otero P, Prósper F, Alfonso A, Paiva B, San Miguel JF. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. J Clin Med 2020;9:E3577. [PMID: 33172026 DOI: 10.3390/jcm9113577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
63 Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, Hewitt SM, Feldman SA, Kochenderfer JN. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Mol Ther 2021;29:702-17. [PMID: 33129371 DOI: 10.1016/j.ymthe.2020.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
64 Bobin A, Liuu E, Moya N, Gruchet C, Sabirou F, Lévy A, Gardeney H, Nsiala L, Cailly L, Guidez S, Tomowiak C, Systchenko T, Javaugue V, Durand G, Leleu X, Puyade M. Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. Cancers (Basel) 2020;12:E2885. [PMID: 33050025 DOI: 10.3390/cancers12102885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
65 Rodríguez-Lobato LG, Ganzetti M, Fernández de Larrea C, Hudecek M, Einsele H, Danhof S. CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Front Oncol 2020;10:1243. [PMID: 32850376 DOI: 10.3389/fonc.2020.01243] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 24.0] [Reference Citation Analysis]
66 Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clin Cancer Res 2020;26:1541-54. [PMID: 31672768 DOI: 10.1158/1078-0432.CCR-19-2111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
67 Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 2019;8:E997. [PMID: 31323969 DOI: 10.3390/jcm8070997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
68 Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol 2020;38:3794-804. [PMID: 32701411 DOI: 10.1200/JCO.20.01342] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 42.0] [Reference Citation Analysis]
69 Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, Zhang X. Recent advances in CAR-T cell engineering. J Hematol Oncol 2020;13:86. [PMID: 32616000 DOI: 10.1186/s13045-020-00910-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 29.0] [Reference Citation Analysis]
70 Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J 2021;11:116. [PMID: 34145225 DOI: 10.1038/s41408-021-00507-2] [Reference Citation Analysis]
71 Razeghian E, Nasution MKM, Rahman HS, Gardanova ZR, Abdelbasset WK, Aravindhan S, Bokov DO, Suksatan W, Nakhaei P, Shariatzadeh S, Marofi F, Yazdanifar M, Shamlou S, Motavalli R, Khiavi FM. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Res Ther 2021;12:428. [PMID: 34321099 DOI: 10.1186/s13287-021-02510-7] [Reference Citation Analysis]
72 Canny SP, Jackson SW. B Cells in Systemic Lupus Erythematosus: From Disease Mechanisms to Targeted Therapies. Rheum Dis Clin North Am 2021;47:395-413. [PMID: 34215370 DOI: 10.1016/j.rdc.2021.04.006] [Reference Citation Analysis]
73 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Britten CM, Shalabi A, Hoos A. Industrializing engineered autologous T cells as medicines for solid tumours. Nat Rev Drug Discov 2021;20:476-88. [PMID: 33833444 DOI: 10.1038/s41573-021-00175-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Mohty R, Gauthier J. Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. Bone Marrow Transplant 2021. [PMID: 34290380 DOI: 10.1038/s41409-021-01420-9] [Reference Citation Analysis]
76 Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021;11:120. [PMID: 34168119 DOI: 10.1038/s41408-021-00505-4] [Reference Citation Analysis]
77 Dal'bo N, Patel R, Parikh R, Shah SP, Guha A, Dani SS, Ganatra S. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med 2020;22:62. [PMID: 33162729 DOI: 10.1007/s11936-020-00867-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
78 Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020;17:418-34. [PMID: 32242094 DOI: 10.1038/s41571-020-0347-5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 72.0] [Reference Citation Analysis]
79 Tan AHJ, Vinanica N, Campana D. Chimeric antigen receptor-T cells with cytokine neutralizing capacity. Blood Adv 2020;4:1419-31. [PMID: 32271901 DOI: 10.1182/bloodadvances.2019001287] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
80 Watanabe N, McKenna MK, Rosewell Shaw A, Suzuki M. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther 2021;29:505-20. [PMID: 33130314 DOI: 10.1016/j.ymthe.2020.10.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
81 Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:59. [PMID: 31186046 DOI: 10.1186/s13045-019-0746-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 22.5] [Reference Citation Analysis]
82 Mateos MV, Bladé J, Bringhen S, Ocio EM, Efebera Y, Pour L, Gay F, Sonneveld P, Gullbo J, Richardson PG. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. J Clin Med 2020;9:E3120. [PMID: 32992506 DOI: 10.3390/jcm9103120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
83 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
84 Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, Wang W, Heald DL. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs 2020;12:1688616. [PMID: 31852337 DOI: 10.1080/19420862.2019.1688616] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
85 Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu XH. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021;11:238. [PMID: 33567640 DOI: 10.3390/biom11020238] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Immunotherapy for Multiple Myeloma. Cancers (Basel). 2019;11:2009. [PMID: 31842518 DOI: 10.3390/cancers11122009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
87 Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer 2020;8:e000990. [PMID: 32900862 DOI: 10.1136/jitc-2020-000990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
88 Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers (Basel). 2021;13. [PMID: 33450845 DOI: 10.3390/cancers13020271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
89 Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol 2020;10:606368. [PMID: 33585226 DOI: 10.3389/fonc.2020.606368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
90 de Larrea CF, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, Purdon TJ, Ponomarev V, Wendel HG, Brentjens RJ, Smith EL. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discov 2020;1:146-54. [PMID: 33089218 DOI: 10.1158/2643-3230.bcd-20-0020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 29.0] [Reference Citation Analysis]
91 Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers (Basel) 2021;13:2712. [PMID: 34072645 DOI: 10.3390/cancers13112712] [Reference Citation Analysis]
92 Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 2021;18:379-93. [PMID: 33633361 DOI: 10.1038/s41571-021-00476-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
93 Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2020;26:e7-e15. [PMID: 31526843 DOI: 10.1016/j.bbmt.2019.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
94 Shah UA, Mailankody S. CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Pract Res Clin Haematol 2020;33:101141. [PMID: 32139020 DOI: 10.1016/j.beha.2020.101141] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
95 Gu YM, Zhuo Y, Chen LQ, Yuan Y. The Clinical Application of Neoantigens in Esophageal Cancer. Front Oncol 2021;11:703517. [PMID: 34386424 DOI: 10.3389/fonc.2021.703517] [Reference Citation Analysis]
96 Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol 2019;12:120. [PMID: 31752943 DOI: 10.1186/s13045-019-0823-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
97 Utley A, Lipchick B, Lee KP, Nikiforov MA. Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells. Cancers (Basel) 2020;12:E2117. [PMID: 32751699 DOI: 10.3390/cancers12082117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Li C, Mei H, Hu Y. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Brief Funct Genomics 2020;19:175-82. [PMID: 31950135 DOI: 10.1093/bfgp/elz042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
99 Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL, Green DJ, Riddell SR. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 2019;134:1585-97. [PMID: 31558469 DOI: 10.1182/blood.2019000050] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 83.0] [Reference Citation Analysis]
100 Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol 2020;22:1425-38. [PMID: 32615600 DOI: 10.1093/neuonc/noaa154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
101 Leone P, Solimando AG, Malerba E, Fasano R, Buonavoglia A, Pappagallo F, De Re V, Argentiero A, Silvestris N, Vacca A, Racanelli V. Actors on the Scene: Immune Cells in the Myeloma Niche. Front Oncol 2020;10:599098. [PMID: 33194767 DOI: 10.3389/fonc.2020.599098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
102 Rader C. Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol 2020;65:9-16. [PMID: 31841859 DOI: 10.1016/j.copbio.2019.11.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
103 Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021;21:145-61. [PMID: 33483715 DOI: 10.1038/s41568-020-00323-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 25.0] [Reference Citation Analysis]
104 van der Schans JJ, van de Donk NWCJ, Mutis T. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Front Oncol 2020;10:1362. [PMID: 32850436 DOI: 10.3389/fonc.2020.01362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
105 Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, Cheng H, Qiao J, Wang Y, Wang Y, Gao L, Shi M, Sang W, Zhu F, Li D, Sun H, Wu Q, Qi Y, Li H, Wang X, Li Z, Liu H, Zheng J, Qian W, Zhang X, Xu K. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Front Immunol 2021;12:611366. [PMID: 33708205 DOI: 10.3389/fimmu.2021.611366] [Reference Citation Analysis]
106 Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, Hamze M, Valton J, Smith J, Djuretic I, Chaparro-Riggers J, Sasu BJ. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. Mol Ther 2020;28:2237-51. [PMID: 32592688 DOI: 10.1016/j.ymthe.2020.06.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
107 Wong AH, Shin EM, Tergaonkar V, Chng WJ. Targeting NF-κB Signaling for Multiple Myeloma. Cancers (Basel) 2020;12:E2203. [PMID: 32781681 DOI: 10.3390/cancers12082203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
108 Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol 2019;10:2109. [PMID: 31552045 DOI: 10.3389/fimmu.2019.02109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
109 Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer 2021;9:e002287. [PMID: 34353848 DOI: 10.1136/jitc-2020-002287] [Reference Citation Analysis]
110 Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J Clin Med 2020;9:E2166. [PMID: 32659909 DOI: 10.3390/jcm9072166] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
111 Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv 2020;4:4195-207. [PMID: 32898244 DOI: 10.1182/bloodadvances.2020002524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
112 Lindo L, Wilkinson LH, Hay KA. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Front Immunol 2020;11:618387. [PMID: 33643299 DOI: 10.3389/fimmu.2020.618387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J 2021;11:146. [PMID: 34392311 DOI: 10.1038/s41408-021-00537-w] [Reference Citation Analysis]
114 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
115 Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Mol Ther Oncolytics 2021;20:625-33. [PMID: 33816781 DOI: 10.1016/j.omto.2021.03.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR Cell Therapy-More Than a Pipe Dream. Front Immunol 2020;11:618427. [PMID: 33488631 DOI: 10.3389/fimmu.2020.618427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
117 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
118 Shao M, Yu Q, Teng X, Guo X, Wei G, Xu H, Cui J, Chang AH, Hu Y, Huang H. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplant 2021;56:1642-50. [PMID: 33608658 DOI: 10.1038/s41409-021-01226-9] [Reference Citation Analysis]
119 Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The Application of CAR-T Cells in Haematological Malignancies. Arch Immunol Ther Exp (Warsz) 2020;68:34. [PMID: 33156409 DOI: 10.1007/s00005-020-00599-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol 2020;11:888. [PMID: 32477359 DOI: 10.3389/fimmu.2020.00888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
121 Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther 2020;28:2320-39. [PMID: 32979309 DOI: 10.1016/j.ymthe.2020.09.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 33.0] [Reference Citation Analysis]
122 Visram A, Suska A, Jurczyszyn A, Gonsalves WI. Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treat Res Commun 2021;28:100414. [PMID: 34174530 DOI: 10.1016/j.ctarc.2021.100414] [Reference Citation Analysis]
123 Gorbet MJ, Singh A, Mao C, Fiering S, Ranjan A. Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits. Int J Hyperthermia 2020;37:18-33. [PMID: 33426995 DOI: 10.1080/02656736.2020.1802519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
124 Mika T, Ladigan-Badura S, Maghnouj A, Mustafa B, Klein-Scory S, Baraniskin A, Döhring S, Fuchs I, Ehl S, Hahn SA, Schroers R. Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. Front Oncol 2020;10:568056. [PMID: 33363008 DOI: 10.3389/fonc.2020.568056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere 2021;5:e528. [PMID: 33554050 DOI: 10.1097/HS9.0000000000000528] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
126 Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, Lubben B, Adebayo O, Khaskiah A, Azab AK. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers (Basel) 2021;13:2853. [PMID: 34201007 DOI: 10.3390/cancers13122853] [Reference Citation Analysis]
127 Davis LN, Sherbenou DW. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel) 2021;13:1686. [PMID: 33918370 DOI: 10.3390/cancers13071686] [Reference Citation Analysis]
128 Kang W, Ding C, Zheng D, Ma X, Yi L, Tong X, Wu C, Xue C, Yu Y, Zhou Q. Nanobody Conjugates for Targeted Cancer Therapy and Imaging. Technol Cancer Res Treat 2021;20:15330338211010117. [PMID: 33929911 DOI: 10.1177/15330338211010117] [Reference Citation Analysis]
129 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 26.0] [Reference Citation Analysis]
130 Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol 2020;13:150. [PMID: 33168044 DOI: 10.1186/s13045-020-00980-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
131 Yan L, Shang J, Shi X, Kang H, Liu W, Xu N, Liu Y, Chen G, Kang L, Gong F, Tang F, Yu L, Wu D, Fu C. Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells. Am J Hematol 2020;95:E20-3. [PMID: 31637745 DOI: 10.1002/ajh.25664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Wang X, Cabrera FG, Sharp KL, Spencer DM, Foster AE, Bayle JH. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins. Mol Ther 2021;29:718-33. [PMID: 33554868 DOI: 10.1016/j.ymthe.2020.10.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
133 Wäsch R, Munder M, Marks R. Teaming up for CAR-T cell therapy. Haematologica 2019;104:2335-6. [PMID: 31787616 DOI: 10.3324/haematol.2019.228676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
134 Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv 2019;3:2812-5. [PMID: 31575532 DOI: 10.1182/bloodadvances.2019000600] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 39.0] [Reference Citation Analysis]
135 Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Cancer Med 2021;10:563-74. [PMID: 33356013 DOI: 10.1002/cam4.3624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
136 Brechbühl S, Bacher U, Jeker B, Pabst T. Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. Mediterr J Hematol Infect Dis 2021;13:e2021012. [PMID: 33489051 DOI: 10.4084/MJHID.2021.012] [Reference Citation Analysis]
137 Li P, Zhou L, Ye S, Zhang W, Wang J, Tang X, Liu J, Xu Y, Qian W, Liang A. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis. Front Immunol 2021;12:638678. [PMID: 34335561 DOI: 10.3389/fimmu.2021.638678] [Reference Citation Analysis]
138 Bell M, Gottschalk S. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front Immunol 2021;12:684642. [PMID: 34177932 DOI: 10.3389/fimmu.2021.684642] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Penter L, Wu CJ. Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. J Clin Invest 2020;130:1595-607. [PMID: 31985488 DOI: 10.1172/JCI129209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
140 Miazek-Zapala N, Slusarczyk A, Kusowska A, Zapala P, Kubacz M, Winiarska M, Bobrowicz M. The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 2021;10:1511. [PMID: 34203935 DOI: 10.3390/cells10061511] [Reference Citation Analysis]
141 Çınar Ö, Brzezicha B, Grunert C, Kloetzel PM, Beier C, Peuker CA, Keller U, Pezzutto A, Busse A. High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. J Immunother Cancer 2021;9:e002410. [PMID: 34330762 DOI: 10.1136/jitc-2021-002410] [Reference Citation Analysis]
142 Nishida H, Yamada T. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. J Oncol 2019;2019:6084012. [PMID: 31781214 DOI: 10.1155/2019/6084012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
143 Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang B, Yin Q, Wei X, Zhou H, Li L, Xu B, Zhang J, Song Y, Gao Q. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer 2020;8:e000927. [PMID: 32792360 DOI: 10.1136/jitc-2020-000927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer 2019;18:154. [PMID: 31684964 DOI: 10.1186/s12943-019-1092-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
145 Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 2021;35:752-63. [PMID: 32632095 DOI: 10.1038/s41375-020-0951-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
146 García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front Immunol 2020;11:1128. [PMID: 32582204 DOI: 10.3389/fimmu.2020.01128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
147 Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 2020;34:2150-62. [PMID: 32060401 DOI: 10.1038/s41375-020-0745-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
148 Baumeister SHC, Rambaldi B, Shapiro RM, Romee R. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Front Immunol 2020;11:191. [PMID: 32117310 DOI: 10.3389/fimmu.2020.00191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
149 Suzuki K. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Int J Hematol 2020;111:512-8. [PMID: 32125606 DOI: 10.1007/s12185-020-02841-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020;10:94. [PMID: 32989217 DOI: 10.1038/s41408-020-00359-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 28.0] [Reference Citation Analysis]
151 Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A, Bachmann M. Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. Cancers (Basel) 2020;12:E1302. [PMID: 32455621 DOI: 10.3390/cancers12051302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
152 McCarthy MW. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine. Expert Rev Anti Infect Ther 2020;18:799-805. [PMID: 32366131 DOI: 10.1080/14787210.2020.1761333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
153 Battram AM, Bachiller M, Lopez V, Fernández de Larrea C, Urbano-Ispizua A, Martín-Antonio B. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel) 2021;13:3534. [PMID: 34298748 DOI: 10.3390/cancers13143534] [Reference Citation Analysis]
154 Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol 2021;11:648655. [PMID: 33842363 DOI: 10.3389/fonc.2021.648655] [Reference Citation Analysis]
155 Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. Ther Adv Vaccines Immunother 2020;8:2515135520927164. [PMID: 32524070 DOI: 10.1177/2515135520927164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
156 Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kröger N. Development of CAR-T cell therapies for multiple myeloma. Leukemia 2020;34:2317-32. [PMID: 32572190 DOI: 10.1038/s41375-020-0930-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 22.0] [Reference Citation Analysis]
157 Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica 2019;104:2358-60. [PMID: 31439675 DOI: 10.3324/haematol.2019.224204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
158 Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 2020;4:3776-87. [PMID: 32780846 DOI: 10.1182/bloodadvances.2020002509] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 27.0] [Reference Citation Analysis]
159 Pang Y, Shao H, Yang Z, Fan L, Liu W, Shi J, Wang Y, Han Y, Yang L. The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen. Front Oncol 2020;10:1617. [PMID: 32984029 DOI: 10.3389/fonc.2020.01617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
160 Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 2020;13:29. [PMID: 32245497 DOI: 10.1186/s13045-020-00862-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 30.0] [Reference Citation Analysis]
161 Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol 2019;345:103964. [PMID: 31492448 DOI: 10.1016/j.cellimm.2019.103964] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
162 Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. Front Immunol 2021;12:663201. [PMID: 33995389 DOI: 10.3389/fimmu.2021.663201] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Kampa M, Notas G, Stathopoulos EN, Tsapis A, Castanas E. The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer. Front Oncol 2020;10:827. [PMID: 32612943 DOI: 10.3389/fonc.2020.00827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
164 Lu A, Liu H, Shi R, Cai Y, Ma J, Shao L, Rong V, Gkitsas N, Lei H, Highfill SL, Panch S, Stroncek DF, Jin P. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. J Transl Med 2020;18:191. [PMID: 32384903 DOI: 10.1186/s12967-020-02358-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
165 Sivaraj D, Chen K, Chattopadhyay A, Henn D, Wu W, Noishiki C, Magbual NJ, Mittal S, Mermin-Bunnell AM, Bonham CA, Trotsyuk AA, Barrera JA, Padmanabhan J, Januszyk M, Gurtner GC. Hydrogel Scaffolds to Deliver Cell Therapies for Wound Healing. Front Bioeng Biotechnol 2021;9:660145. [PMID: 34012956 DOI: 10.3389/fbioe.2021.660145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, Manier S. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv 2021;5:3016-20. [PMID: 34351389 DOI: 10.1182/bloodadvances.2021004176] [Reference Citation Analysis]
167 Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. Cancers (Basel) 2020;12:E1075. [PMID: 32357417 DOI: 10.3390/cancers12051075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
168 Leblay N, Maity R, Hasan F, Neri P. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. Front Oncol 2020;10:636. [PMID: 32432039 DOI: 10.3389/fonc.2020.00636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
169 Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM, Yang EH, Zaha V, Barac A, Liu JE. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. J Am Coll Cardiol 2019;74:3153-63. [PMID: 31856973 DOI: 10.1016/j.jacc.2019.10.049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 32.0] [Reference Citation Analysis]
170 van Nieuwenhuijzen N, Frunt R, May AM, Minnema MC. Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. Blood Cancer J 2021;11:44. [PMID: 33649328 DOI: 10.1038/s41408-021-00441-3] [Reference Citation Analysis]
171 Weiler S, Nairz M. TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia. Front Oncol 2021;11:627223. [PMID: 33842333 DOI: 10.3389/fonc.2021.627223] [Reference Citation Analysis]
172 Sidana S, Shah N. CAR T-cell therapy: is it prime time in myeloma? Blood Adv 2019;3:3473-80. [PMID: 31714964 DOI: 10.1182/bloodadvances.2019000370] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
173 Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol 2020;86:1678-89. [PMID: 32175617 DOI: 10.1111/bcp.14281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv 2020;4:3295-301. [PMID: 32706892 DOI: 10.1182/bloodadvances.2020002037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
175 Bobin A, Gardeney H, Sabirou F, Gruchet C, Lévy A, Nsiala L, Cailly L, Tomowiak C, Torregrosa J, Guidez S, Leleu X. The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. Front Oncol 2020;10:676. [PMID: 32435618 DOI: 10.3389/fonc.2020.00676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
176 Lopes R, Ferreira BV, Caetano J, Barahona F, Carneiro EA, João C. Boosting Immunity against Multiple Myeloma. Cancers (Basel) 2021;13:1221. [PMID: 33799565 DOI: 10.3390/cancers13061221] [Reference Citation Analysis]
177 Huang CP, Yang CY, Shyr CR. Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases. Cell Transplant 2021;30:9636897211011995. [PMID: 33975464 DOI: 10.1177/09636897211011995] [Reference Citation Analysis]
178 Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, Kline J. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer 2020;8:e000286. [PMID: 31940591 DOI: 10.1136/jitc-2019-000286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
179 Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection. Onco Targets Ther 2020;13:6405-16. [PMID: 32669858 DOI: 10.2147/OTT.S227166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine Release Syndrome: Current Perspectives. Immunotargets Ther 2019;8:43-52. [PMID: 31754614 DOI: 10.2147/ITT.S202015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
181 Kasahara Y, Shin C, Kubo N, Mihara K, Iwabuchi H, Takachi T, Imamura M, Saitoh A, Imai C. Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. Clin Transl Immunology 2020;9:e1147. [PMID: 32670576 DOI: 10.1002/cti2.1147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
182 Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis 2020;76:63-71. [PMID: 31973908 DOI: 10.1053/j.ajkd.2019.10.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
183 Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, Liu C, Zhou J. Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Front Oncol 2019;9:1237. [PMID: 31824840 DOI: 10.3389/fonc.2019.01237] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
184 Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020;136:925-35. [PMID: 32582924 DOI: 10.1182/blood.2019004000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
185 Stock S, Schmitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci 2019;20:E6223. [PMID: 31835562 DOI: 10.3390/ijms20246223] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
186 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2020;12:E1473. [PMID: 32516895 DOI: 10.3390/cancers12061473] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
187 Rustad EH, Boyle EM. Monitoring minimal residual disease in the bone marrow using next generation sequencing. Best Pract Res Clin Haematol 2020;33:101149. [PMID: 32139014 DOI: 10.1016/j.beha.2020.101149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
188 Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun 2020;11:283. [PMID: 31941907 DOI: 10.1038/s41467-019-14119-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
189 Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 2020;20:321-34. [PMID: 32005979 DOI: 10.1038/s41577-019-0269-6] [Cited by in Crossref: 155] [Cited by in F6Publishing: 111] [Article Influence: 155.0] [Reference Citation Analysis]
190 Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther 2021. [PMID: 33753909 DOI: 10.1038/s41434-021-00246-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
191 Liu C, Ayyar VS, Zheng X, Chen W, Zheng S, Mody H, Wang W, Heald D, Singh AP, Cao Y. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans. Clin Pharmacol Ther 2021;109:716-27. [PMID: 33002189 DOI: 10.1002/cpt.2040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
192 Sperling AS, Anderson KC. Facts and Hopes in Multiple Myeloma Immunotherapy. Clin Cancer Res 2021;27:4468-77. [PMID: 33771856 DOI: 10.1158/1078-0432.CCR-20-3600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Liu D. Cancer biomarkers for targeted therapy. Biomark Res 2019;7:25. [PMID: 31807308 DOI: 10.1186/s40364-019-0178-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
194 Hosen N. Chimeric antigen receptor T-cell therapy for multiple myeloma. Int J Hematol. 2020;111:530-534. [PMID: 31981097 DOI: 10.1007/s12185-020-02827-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
195 Wudhikarn K, Mailankody S, Smith EL. Future of CAR T cells in multiple myeloma. Hematology Am Soc Hematol Educ Program 2020;2020:272-9. [PMID: 33275747 DOI: 10.1182/hematology.2020000111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
196 Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021;184:1575-88. [PMID: 33675691 DOI: 10.1016/j.cell.2021.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
197 Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020;9:E983. [PMID: 32316105 DOI: 10.3390/cells9040983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
198 Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, Polo A, Mangioni M, Salierno M, Berger M, Pessolano R, Saglio F, Gottardi D, Rota-Scalabrini D, Grignani G, Fizzotti M, Ferrero I, Frascione PMM, D'Ambrosio L, Gaidano V, Gammaitoni L, Sangiolo D, Saglietto A, Vassallo E, Cignetti A, Aglietta M, Fagioli F. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. J Clin Med 2021;10:1173. [PMID: 33799685 DOI: 10.3390/jcm10061173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Zambello R, Barilà G, Manni S, Piazza F, Semenzato G. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells 2020;9:E768. [PMID: 32245149 DOI: 10.3390/cells9030768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
200 Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2020;11:2040620720979813. [PMID: 33403093 DOI: 10.1177/2040620720979813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
201 Mostafa Kamel Y. CAR-T Therapy, the End of a Chapter or the Beginning of a New One? Cancers (Basel) 2021;13:853. [PMID: 33670515 DOI: 10.3390/cancers13040853] [Reference Citation Analysis]
202 Goldsmith SR, Fiala MA, Wang B, Schroeder MA, Wildes TM, Ghobadi A, Stockerl-Goldstein K, Vij R. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol 2020;99:1041-8. [PMID: 32130471 DOI: 10.1007/s00277-020-03970-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
203 Liang X, Huang Y, Li D, Yang X, Jiang L, Zhou W, Su J, Chen N, Wang W. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. Gene Ther 2021. [PMID: 33953316 DOI: 10.1038/s41434-021-00257-7] [Reference Citation Analysis]
204 Cazaubiel T, Mulas O, Montes L, Schavgoulidze A, Avet-Loiseau H, Corre J, Perrot A. Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers (Basel) 2020;12:E3497. [PMID: 33255368 DOI: 10.3390/cancers12123497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv 2020;4:2899-911. [PMID: 32589729 DOI: 10.1182/bloodadvances.2019001346] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
206 Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 2021;14:66. [PMID: 33879198 DOI: 10.1186/s13045-021-01077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
207 Xu J, Ming X, Wang C, Xu B, Xiao Y. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports. Medicine (Baltimore) 2021;100:e25784. [PMID: 33950974 DOI: 10.1097/MD.0000000000025784] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 van de Donk NWCJ, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov 2021;2:302-18. [PMID: 34386775 DOI: 10.1158/2643-3230.bcd-20-0227] [Reference Citation Analysis]
209 Noh JY, Seo H, Lee J, Jung H. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. Int J Mol Sci 2020;21:E8000. [PMID: 33121189 DOI: 10.3390/ijms21218000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
210 Zhao K, Xu KL. [Structural evolution and prospect of chimeric antigen receptor T cell (CAR-T cell)]. Zhonghua Xue Ye Xue Za Zhi 2020;41:964-8. [PMID: 33333707 DOI: 10.3760/cma.j.issn.0253-2727.2020.11.019] [Reference Citation Analysis]
211 Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Adv 2019;3:2487-90. [PMID: 31451444 DOI: 10.1182/bloodadvances.2019000466] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
212 Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C. The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 2019;19:855. [PMID: 31464608 DOI: 10.1186/s12885-019-6080-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Regidor B, Sutanto C, Berenson JR. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy. Target Oncol 2021;16:503-15. [PMID: 34097243 DOI: 10.1007/s11523-021-00821-6] [Reference Citation Analysis]
214 Sessa M, Cavazzini F, Cavallari M, Rigolin GM, Cuneo A. A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes (Basel) 2020;11:E1453. [PMID: 33287156 DOI: 10.3390/genes11121453] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Berdeja JG. Practical aspects of building a new immunotherapy program: the future of cell therapy. Hematology Am Soc Hematol Educ Program 2020;2020:579-84. [PMID: 33275680 DOI: 10.1182/hematology.2020000144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Marofi F, Saleh MM, Rahman HS, Suksatan W, Al-Gazally ME, Abdelbasset WK, Thangavelu L, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Pathak Y, Naimi A, Baradaran B, Nikoo M, Khiavi FM. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther 2021;12:374. [PMID: 34215336 DOI: 10.1186/s13287-021-02462-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J, Yuan H, de Bruijn JD, van de Donk NWCJ, Zweegman S, Themeli M, Groen R, O'Dwyer M, Mutis T. CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma. Hemasphere 2021;5:e596. [PMID: 34131635 DOI: 10.1097/HS9.0000000000000596] [Reference Citation Analysis]
218 Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica 2020;105:2358-67. [PMID: 33054076 DOI: 10.3324/haematol.2020.247015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
219 Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nuñez N, Simonis A, Pfister S, Wilk CM, McHugh D, Friemel J, Müller AM, Becher B, Münz C, van den Broek M, Neri D, Manz MG. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 2020;34:2688-703. [PMID: 32358567 DOI: 10.1038/s41375-020-0818-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
220 Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ Sci B 2020;21:29-41. [PMID: 31898440 DOI: 10.1631/jzus.B1900351] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
221 Abousaway O, Rakhshandehroo T, Van den Abbeele AD, Kircher MF, Rashidian M. Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics 2021;5:90-112. [PMID: 33391977 DOI: 10.7150/ntno.50860] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
222 Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest 2020;130:1565-75. [PMID: 32149732 DOI: 10.1172/JCI129205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
223 Gonzalez Castro LN, Dietrich J. Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neurooncol Pract 2021;8:259-65. [PMID: 34055373 DOI: 10.1093/nop/npaa080] [Reference Citation Analysis]
224 Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Fu C, Tang X, Dai H, Chen J, Wu D, Yu L. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomark Res 2020;8:14. [PMID: 32435496 DOI: 10.1186/s40364-020-00192-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
225 Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020;11:577027. [PMID: 33391257 DOI: 10.3389/fimmu.2020.577027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
226 Strohl WR, Naso M. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies (Basel) 2019;8:E41. [PMID: 31544847 DOI: 10.3390/antib8030041] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 21.5] [Reference Citation Analysis]
227 Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Front Pharmacol 2020;11:544754. [PMID: 33343342 DOI: 10.3389/fphar.2020.544754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Pillarisetti K, Edavettal S, Mendonça M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020;135:1232-43. [PMID: 32040549 DOI: 10.1182/blood.2019003342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
229 Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep 2021;15:90. [PMID: 33608053 DOI: 10.1186/s13256-020-02598-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
230 Fang Y, Hou J. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res 2021;8:9. [PMID: 33504363 DOI: 10.1186/s40779-021-00302-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
231 Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci 2021;18:1786-97. [PMID: 33746596 DOI: 10.7150/ijms.46811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 2020;4:4538-49. [PMID: 32956453 DOI: 10.1182/bloodadvances.2020002393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
233 Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, Einsele H, Hudecek M, Bonig H, Ivics Z. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther 2021. [PMID: 33846552 DOI: 10.1038/s41434-021-00254-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
234 Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2021. [PMID: 34002066 DOI: 10.1038/s41577-021-00547-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
235 Alhallak K, Sun J, Wasden K, Guenthner N, O'Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 2021;35:2346-57. [PMID: 33479469 DOI: 10.1038/s41375-021-01127-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]